Karishma Profile Karishma

Outcome of covid-19 positive patients with type 2 diabetes and polypharmacy: an examination of a tertiary hospital cohort

  • Authors Details :  
  • Mohammed Danjuma,  
  • Bhagya Sree,  
  • Unwam Jumbo,  
  • Lina Al Tarawneh,  
  • Rowan Mesilhy,  
  • Aly Roa,  
  • Hend Alobaidi,  
  • Amal H Elmasaad,  
  • Gamal Alfitori,  
  • Islam Elzouki,  
  • Lina Naseralallah

Journal title : Yemen Journal of Medicine

Publisher : Mansa STM Publishers

Online ISSN : 2583-4614

Page Number : 117-122

Journal volume : 04

Journal issue : 01

94 Views Original Article

Background: COVID-19-positive patients are at increased risk of adverse clinical outcomes, with type 2 diabetes cohorts at substantially higher risk compared to the general population. The additional role of diabetic and non-diabetic polypharmacy in these patients' clinical course has remained unexamined. In this study we have comprehensively examined the role of polypharmacy in the determination of mortality outcomes in patients with COVID-19 clinical syndrome. Methods: We retrospectively examined case notes and electronic records of N = 497 patients with type 2 diabetes and COVID-19 infection. We ascertained the number of medications each patient was taking and used this to categorize the study cohort into diabetic [n = 246] (5 or more diabetic medications), and non-diabetic polypharmacy [n = 251] (5 or more non-diabetic medications). The primary outcome was the need for intensive care admission between the two groups. Results: In patients with “non-diabetic polypharmacy” (>5 medications), advancing age, and higher HBA1c levels, were associated with increased risk of Intensive care admission (OR 1.06 [CI 1.03-1.07], P = <0001), (OR 1.01 [CI 1.01- 1.20], P 0.017), respectively. Patients taking 5 or more non-diabetic medications had an increased likelihood of admission into the intensive care unit compared to those on lower medication thresholds (OR = 1.7; CI = 1.1 to 1.3; p-value = <0.0006). Conclusion: In an inpatient cohort of type 2 diabetic patients with COVID-19, non-diabetic polypharmacy was associated with a multiplicative risk of intensive care admissions. This will necessitate the need for periodic medication reviews in these cohorts of patients to mitigate these potential risks and improve clinical outcomes.

Article DOI & Crossmark Data

DOI : https://doi.org/10.63475/yjm.v4i1.0051

Article Subject Details


Article Keywords Details



Article File

Full Text PDF



More Article by Karishma

Learning and teaching in internal medicine teams in hamad general hospital, qatar: a resident journey in acgme-i accredited program outside the united states

The internal medicine residency program at hamad medical corporation (hmc) is accredited by the accreditation council for graduate medical education–international (acgme-i). upon c...

Air pollution, health outcomes, and environmental justice in the mid-atlantic state city: a public health lesson from a 15-year perspective (2005-2019)

The city that never sleeps, a vibrant tapestry of dense neighborhoods and relentless energy, has long grappled with the pervasive challenge of air pollution. the very dynamism that...

Cardiorenal, renocardiac, and reno-cardiocardiac syndromes: an updated review on general definitions, pathophysiology, and therapies (part 1)

Background: acute and chronic heart or kidney failure affect each other in cardiorenal syndromes (crs). in crs, hemodynamic and non-hemodynamic changes occur, causing acute or prog...

Dignity therapy for individuals with severe mental illness: a holistic approach to care –a narrative review

Dignity therapy (dt) is an evidence-based psychotherapeutic approach originally designed to alleviate emotional and existential distress in patients with terminal illnesses. while ...